Research Paper Volume 16, Issue 8 pp 7188—7216
Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer
Figure 6. Correlation between TPX2 expression and the clinicopathological features of breast cancer patients for (A) T stage, (B) N stage, (C) M stage, (D) pathologic stage, (E) PAM50, (F) Age, (G) radiation therapy, (H) race and (I) histologic type. *P < 0.05, **P < 0.01, ***P < 0.001.